摘要
目的：探讨雾化吸入莫西沙星治疗慢性阻塞性肺疾病合并呼吸衰竭的临床疗效.方法：以我院2012年12月1日~2014年12月1日期间收治的慢阻肺合并呼吸衰竭患者共57例作为观察组,在常规治疗的基础上雾化吸入莫西沙星进行治疗,并选择同期收治的53例患者作为对照组,在常规治疗基础上雾化吸入沙丁胺醇进行治疗.观察并统计两组患者治疗前后主观症状及通气功能的改善情况,比较不良反应率差异.结果：治疗前两组的主观症状及通气功能差异均无统计学意义（P 〉0.05）;而治疗后,观察组的主观症状评分明显降低,FVC、FEV1和PEF等通气功能指标则明显升高,均显著优于对照组;并且,观察组的不良反应率仅为7.02%（4/57）,显著低于对照组的22.64%（12/53）,两组间差异比较均具有统计学意义（P 〈0.05）.结论：雾化吸入莫西沙星可有效改善慢阻肺合并呼吸衰竭患者的临床症状及通气功能,安全性高,值得在临床上推广使用.
Objective:To investigate the clinical effect of aerosol inhalation of Moxifloxacin on COPD complicated with respiration failure.Methods:Take the 50 patients with COPD complicated with respiration failure received in our hospital during the period from 1st December 2012 to December 1st 2014 as the observation group,treat them with aerosol nebulization of Moxifloxacin based on routine treatment,select 53 concurrent patients as the control group and treat them with aerosol nebulization of Salbutamol based on routine treatment,observe the improvement in subjective symptoms and ventilation function in both group,compare the difference between the 2groups in the occurrence of adverse reaction.Results:Before treatment,the difference between the 2groups in subjective symptoms and ventilation function was not statistically significant(P>0.05);after treatment,the score of subjective symptoms in observation group declined,FVC,FEV1,PEF and other indexes of ventilation function had become greater and were obviously better than that of the control group;and occurrence rate of adverse reaction was only 7.02%(4/57),while the rate of the control group was 22.64%(12/53),the differences between the 2groups were statistically significant(P<0.05).Conclusion:The aerosol nebulization of Moxifloxacin can effectively the clinical symptoms and ventilation function of patients with COPD complicated with respiration failure,it is safe and worthy of clinical promotion.
出处
《数理医药学杂志》
2015年第10期1499-1500,共2页
Journal of Mathematical Medicine
关键词
莫西沙星
沙丁胺醇
雾化吸入
慢性阻塞性肺病
呼吸衰竭
moxifloxacin
salbutamol
aerosol nebulization
chronic obstructive pulmonary disease(COPD)
respiratory failure
